Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Biotechnology Innovation Organization (BIO)

NJEDA: Ideal Location, Unique State Resources Give Enteris BioPharma Advantage in Global Marketplace

Trenton, NJ, June 25, 2017 — This week’s BIO International Convention gave leaders from New Jersey’s vast life sciences ecosystem the chance to show emerging companies the advantages of establishing themselves within the State, such as its ideal location on the Eastern seaboard and the large number of pharmaceutical giants that currently call the State “home.”

“The Garden State is truly the best place to start a biopharmaceutical company,” New Jersey Economic Development Authority (EDA) Chief Executive Officer (CEO) Melissa Orsen said. Continue reading

BIO International Convention 2017 Closes After Four ‘Breakthrough’ Days in San Diego; BIO 2018 Set for Boston

Washington, DC, June 23, 2017 — The 2017 BIO International Convention (BIO 2017), hosted by the Biotechnology Innovation Organization (BIO), closed yesterday after four days of immersive, compelling programming united under the theme of “Breakthrough.”

BIO 2017 drew 16,123 biotechnology industry leaders from 48 States, the District of Columbia, Puerto Rico and 73 countries to San Diego, the “genomics capital” of the world.

As the largest global biotechnology event, BIO 2017 provided attendees with unique perspectives on the immense opportunities and complex challenges ahead for the industry. Continue reading

Choose New Jersey Showcases State’s Assets, Resources at BIO International 2017 This Week

Princeton, NJ, June 22, 2017 — A delegation representing more than 20 New Jersey organizations, including top life sciences companies, universities, trade associations, State government and Choose New Jersey, Inc. is showcasing New Jersey’s assets and resources for biotechnology companies at the New Jersey Pavilion (Booth #1737) at BIO International 2017, June 19-22 (2017) in San Diego, California.

During the world’s largest biotechnology conference, members of the New Jersey delegation are holding business meetings with executives representing companies in North America, Europe and Asia interested in learning more about the benefits of a New Jersey location. Continue reading

HINJ to Serve as Lead Sponsor of Choose New Jersey’s Annual Reception at BIO International on June 19 in San Diego

New Brunswick, NJ, May 19, 2016 — The HealthCare Institute of New Jersey (HINJ) will serve, once again, as the lead sponsor of Choose New Jersey’s annual reception at BIO International Convention on Monday, June 19 from 5:00 to 7:00 p.m. at Top of the Hyatt at the Grand Hyatt San Diego.

Choose New Jersey will showcase top life sciences companies, universities, trade associations, the State government at its New Jersey Pavilion (Booth #1737) at BIO International 2017, which will be held from June 19 to 22 at the San Diego Convention Center. Continue reading

BIO Offers Video Explaining How Drug Costs Are Really Determined

Washington, DC, April 3, 2017 — Today, much of the public debate surrounding the cost of biopharmaceuticals is focused on the list price of an individual drug or treatment regimen.

However, the list price is not what a manufacturer generally makes on the drug, and it typically has little to do with what a patient has to pay for his or her medicine.

To help put this debate into context, the Biotechnology Innovation Organization (BIO) in October unveiled an educational video today designed to give patients, consumers, policy makers and journalists a better understanding of how prescription drug costs are really determined and where the pharmaceutical dollar actually goes. Continue reading

Biotechnology Innovation Organization Statement on President’s Budget Proposal

Washington, DC, March 20, 2017Biotechnology Innovation Organization (BIO) Senior Vice President for Communications Kenneth Lisaius issued the following statement on March 17 regarding President Donald J. Trump’s budget blueprint:

“While we are still reviewing today’s budget blueprint, we have initial concerns with the proposed reductions in the budgets for biomedical research, public health, and for agencies that play an important role in promoting innovations in agricultural, environmental, and human health.

“We are encouraged by other language in the budget blueprint that seeks to improve the regulatory environment for such innovations. Continue reading

BIO Produces Video Explaining How Drug Costs Are Really Determined

 

Washington, DC, February 11, 2017 — Today, much of the public debate surrounding the cost of biopharmaceuticals is focused on the list price of an individual drug or treatment regimen.

However, the list price is not what a manufacturer generally makes on the drug, and it typically has little to do with what a patient has to pay for his or her medicine.

To help put this debate into context, the Biotechnology Innovation Organization (BIO) is releasing a new educational video today designed to give patients, consumers, policy makers and journalists a better understanding of how prescription drug costs are really determined and where the pharmaceutical dollar actually goes. Continue reading

BIO Video Explains How Drug Costs Are Really Determined

BIO Logo New NameWashington, DC, January 8, 2017 — Today, much of the public debate surrounding the cost of biopharmaceuticals is focused on the list price of an individual drug or treatment regimen.

However, the list price is not what a manufacturer generally makes on the drug, and it typically has little to do with what a patient has to pay for his or her medicine.

To help put this debate into context, the Biotechnology Innovation Organization (BIO) is releasing a new educational video today designed to give patients, consumers, policy makers and journalists a better understanding of how prescription drug costs are really determined and where the pharmaceutical dollar actually goes. Continue reading

BIO Launches Video Explaining How Drug Costs Are Really Determined

BIO Logo New NameWashington, DC, November 9, 2016 — Today, much of the public debate surrounding the cost of biopharmaceuticals is focused on the list price of an individual drug or treatment regimen.

However, the list price is not what a manufacturer generally makes on the drug, and it typically has little to do with what a patient has to pay for his or her medicine.

To help put this debate into context, the Biotechnology Innovation Organization (BIO) is releasing a new educational video today designed to give patients, consumers, policy makers and journalists a better understanding of how prescription drug costs are really determined and where the pharmaceutical dollar actually goes. Continue reading

The Fourth Annual BioNJ CEO Summit Took It OVER the Top; BIO CEO Jim Greenwood Keynotes

BioNJ SquareTrenton, NJ, September 27, 2016 ― The Fourth Annual BioNJ CEO Summit that took place last week, September 23 at the Bridgewater Marriott, brought together some of the most influential leaders in the life sciences industry to share their knowledge, experiences and views on today’s challenging and evolving market access and commercialization environment.

The stellar lineup of speakers dove into the issues and considerations that need to be addressed along the development continuum, including raising capital, pricing, post-launch and politics.

“Because Patients Can’t WaitSM, bringing new treatments and drugs to the Patients who need them is always at the heart of our programs,” said BioNJ President and CEO Debbie Hart. Continue reading